Navigation Links
Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
Date:2/3/2011

INDIANAPOLIS and NEW YORK, Feb. 3, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

"The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body," said Philip Larsen, M.D., Ph.D., chief scientific officer for diabetes drug discovery at Lilly. "This research is an example of regenerative medicine, a new frontier in science that replaces or regenerates new cells, tissues or organs, and while this particular research is early stage, it may ultimately lead to new approaches to treating type 1 diabetes."

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the beta cells, stopping a person's pancreas from producing insulin. Insulin is a hormone that enables people to get energy from food. According to JDRF, in the U.S. alone, as many as three million people have type 1 diabetes.(1)

One research approach to finding novel treatments for type 1 diabetes may be to restore insulin production by regenerating insulin-producing cells within a person's body. This involves triggering the body to grow its own new beta cells, either by growing existing ones – some are usually still active, even in people who have had diabetes for decades – or by creating new ones by reprogramming, which involves converting one type of cell in the body into a different type.  If a therapeutic is developed that will allow for the regeneration of beta cells, it could potentially eliminate the need for insulin.  

The JDRF-Lilly agreement will support a three-year, $1.4 million pre-cli
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Pharma IQ is pleased ... summary of the results from an industry survey conducted ... respondents stated that CROs would be an area of active ... be running 6 or more clinical trials in the BRIC ... Supply USA Summit explores the latest ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... 2013  Actavis, Inc. (NYSE: ACT ) today ... U.S. Securities and Exchange Commission (SEC) a registration statement on ... Warner Chilcott plc (NASDAQ: WCRX ), which ... Chilcott (the "Form S-4"). As previously announced ... have entered into a definitive agreement pursuant to which Actavis ...
Breaking Medicine Technology:Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
(Date:6/19/2013)... 2013 Weight gain and obesity have ... concerns including heart disease, kidney failure and high blood ... excess and unnecessary fat, have many people searching for ... hCG diets to not only allow patients to ... also aim to reduce the risk for many weight-related ...
(Date:6/19/2013)... To survive when your plane goes down on a combat mission, ... the most important item in a survival kit is not a ... Kleyne Hour Power of Water radio show, Orr stated that in ... ahead of guns or even food. , According to Orr, the ... carry on planes in Vietnam. He was the only Navy pilot ...
(Date:6/19/2013)... New York,NY (PRWEB) June 19, 2013 ... company officials at SizeItUp formally announced the ... This smartly renovated van is the latest entry in ... for the year 2013. The completely redesigned 2012 Nissan ... the automobile lovers and critics alike. , Provided with ...
(Date:6/19/2013)... McGuff Pharmaceuticals, Inc. continues to ... (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple ... fomerly known as Delalutin™. We are providing this ... approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate ... our pending ANDA, to date, McGuff has responded to ...
(Date:6/19/2013)... 2013 Audibel Hearing Center is ... tinnitus patients, the A2 with Multiflex Tinnitus Technology. ... ringing in the ears. Although bothersome, tinnitus usually ... body. , Using their patent-pending Multiflex Tinnitus Technology, ... comforting sound stimulus that resonates through the patient’s ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2
... boost emotional well-being in hard times , , THURSDAY, May ... women may actually overspend to try to cheer themselves up, ... found that 79 percent said they,d go on a shopping ... listed "depression" and 60 percent listed "feeling a bit low" ...
... to Improve CBO Modeling and Information for PolicymakersWASHINGTON, ... Fight Chronic Disease policy briefing on Capitol Hill, ... James C. Capretta, M.A., released a white paper, ... Diseases: The Current Context and Potential Enhancements." ...
... Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group practice company, announced today that management ... New York City., ... ... ...
... CITY, Calif., May 21 Genomic Health, Inc. (Nasdaq: ... will present results from three studies at the American ... May 29 - June 2, 2009, at the Orange ... markets the widely-adopted Onco type DX(R) breast cancer ...
... 21 Celator Pharmaceuticals today announced that it ... Inc. (Nasdaq: CEPH ). The ... application of Celator,s proprietary technology to an ongoing ... agreement provides an opportunity to leverage the technology ...
... the importance of hearing healthPISCATAWAY, N.J., May 21 ... Hearing Month in Times Square from ... air a 30-second hearing loss awareness video every hour on ... addition, 18 Siemens representatives will be in Times Square and ...
Cached Medicine News:Health News:Shop 'Til You Drop: You May Feel Better 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:IPC The Hospitalist Company, Inc. to Present at Citi's 2009 Healthcare Services Day 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: